Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Rui'an Biological Technology is a clinical-stage biotechnology company focused on the development of innovative RNA interference (RNAi) therapeutics. Based in Suzhou, China, the company utilizes its proprietary RI-Deliver platform to design and deliver small interfering RNA (siRNA) molecules targeting liver-related and metabolic diseases. Its lead candidate, RA-001, is an siRNA drug designed for the functional cure of chronic Hepatitis B. The company's pipeline also includes programs for hyperlipidemia and other cardiovascular conditions. Ruian Biotech is supported by prominent venture capital firms and operates within the vibrant Suzhou Industrial Park biotech ecosystem.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou Rui'an Biological Technology.